2-(4-methyl-1,3-thiazol-5-yl)ethanol has been researched along with Alzheimer Disease in 1 studies
2-(4-methyl-1,3-thiazol-5-yl)ethanol: the thiazole portion of thiamine; imparts flavor to cooked meats; RN given is for parent cpd; structure
5-(2-hydroxyethyl)-4-methylthiazole : A 1,3-thiazole that is thiazole substituted by a methyl group at position 4 and a 2-hydroxyethyl group at position 5.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " To provide proof of concept for the nomethiazole drug class, selected examples were assayed for restoration of synaptic function in hippocampal slices from AD-transgenic mice, reversal of cognitive deficits, and brain bioavailability of the prodrug and its neuroprotective MZ metabolite." | 1.38 | Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. ( Arancio, O; Fa', M; Luo, J; Qin, Z; Tavassoli, E; Teich, AF; Thatcher, GR; VandeVrede, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qin, Z | 1 |
| Luo, J | 1 |
| VandeVrede, L | 1 |
| Tavassoli, E | 1 |
| Fa', M | 1 |
| Teich, AF | 1 |
| Arancio, O | 1 |
| Thatcher, GR | 1 |
1 other study available for 2-(4-methyl-1,3-thiazol-5-yl)ethanol and Alzheimer Disease
| Article | Year |
|---|---|
Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Avoidance Learning; Biological Availabil | 2012 |